Antisense Oligonucleotide Therapy for B Cell Mediated Cancers
Targets leukemia cells Conjugated for antisense oligonucleotide Targets precursor B cells Monoclonal antibody
Leukemia B cell mediated cancers, diseases and disorders
Antisense compounds have been used to modulate protein expression by binding to a target mRNA encoding the protein. Application of oligonucleotide-based technologies in cancer is promising but has had limited success in vivo due to the ineffective cell-targeting. Better targeting is needed to improve therapeutic efficacy of oligonucleotide-based cancer therapies in vivo. Researchers at the University of California, Davis have developed a precursor B cell (pre-B) acute lymphoblastic leukemia (ALL) cell targeting compound by directly conjugating an antisense oligonucleotide with an anti-CD22 antibody. This method specifically targets a transcription factor identified to be involved in pre-B ALL cell survival. In-vivo therapeutic efficacy has been successfully tested in pre-B ALL xenograft mouse models and Reh cell line, as well as patient-derived leukemia cells. Utilizing this method also provides new opportunities to treat and target B cells associated with leukemia, lymphoma and autoimmune disorders.
9714288
Additional Technologies by these Inventors Tech ID/UC Case 29215/2014-686-0 Related Cases 2014-686-0
USA
